Understanding how certain proteins affect cancer treatment resistance
Role of DeltaNp63 alpha and TIP60 in SCC progression and chemoresistance
This study is looking at how certain proteins might affect the growth of squamous cell carcinoma and why some patients don’t respond well to the chemotherapy drug cisplatin, with the hope of finding better treatment options for those who struggle with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wright State University NIH-funded |
| Lab location | 1 site (Dayton, United States) |
| Project ID | NIH-10996158 on NIH RePORTER |
What this research studies
This research investigates the role of specific proteins, DeltaNp63 alpha and TIP60, in the progression of squamous cell carcinoma (SCC) and their contribution to resistance against the chemotherapy drug cisplatin. By examining how these proteins interact and influence cancer cell behavior, the research aims to uncover new mechanisms that lead to treatment failure. Patients may benefit from this work as it could lead to improved treatment strategies for those whose cancers do not respond to current therapies. The study employs biological models and cell line experiments to explore these interactions and their implications for cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with squamous cell carcinoma who have experienced resistance to cisplatin treatment.
Not a fit: Patients with non-squamous cell carcinoma types or those who have not undergone cisplatin treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with chemoresistant squamous cell carcinoma.
How similar studies have performed: Previous research has shown promising results in understanding cancer resistance mechanisms, suggesting that this approach could yield valuable insights.
Where this research is happening
Dayton, United States
- Wright State University — Dayton, United States (Active)
Researchers
- Principal investigator: Kadakia, Madhavi P — Wright State University
- Study coordinator: Kadakia, Madhavi P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.